BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, Warsch J, Elias R, Chae YK, Kim DW, Warsch S, Ishkanian A, Ikpeazu C, Mudad R, Lopes G, Jahanzeb M. Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. Clin Lung Cancer 2018;19:280-288.e4. [PMID: 29336998 DOI: 10.1016/j.cllc.2017.12.007] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Banna GL, Friedlaender A, Tagliamento M, Mollica V, Cortellini A, Rebuzzi SE, Prelaj A, Naqash AR, Auclin E, Garetto L, Mezquita L, Addeo A. Biological Rationale for Peripheral Blood Cell-Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer. Curr Oncol Rep 2022;24:1851-62. [PMID: 36255605 DOI: 10.1007/s11912-022-01335-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Rebuzzi SE, Prelaj A, Friedlaender A, Cortellini A, Addeo A, Genova C, Naqash AR, Auclin E, Mezquita L, Banna GL. Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. Crit Rev Oncol Hematol 2022;179:103806. [PMID: 36087850 DOI: 10.1016/j.critrevonc.2022.103806] [Reference Citation Analysis]
3 Gannichida A, Nakazawa Y, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Necessity of neutrophil-to-lymphocyte ratio monitoring for hypothyroidism using nivolumab in patients with cancer. World J Clin Oncol 2022; 13(7): 641-651 [DOI: 10.5306/wjco.v13.i7.641] [Reference Citation Analysis]
4 Wang T, Denman D, Bacot SM, Feldman GM. Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. Biomedicines 2022;10:1181. [DOI: 10.3390/biomedicines10051181] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Liu N, Mao J, Tao P, Chi H, Jia W, Dong C. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors. Medicine (Baltimore) 2022;101:e28617. [PMID: 35060536 DOI: 10.1097/MD.0000000000028617] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
6 Luo W, Wang Z, Zhang T, Yang L, Xian J, Li Y, Li W. Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. Precision Clinical Medicine 2021;4:258-70. [DOI: 10.1093/pcmedi/pbab027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
7 Wu Y, Wu H, Lin M, Liu T, Li J. Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients. Transl Oncol 2021;15:101268. [PMID: 34800914 DOI: 10.1016/j.tranon.2021.101268] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Sibille A, Henket M, Corhay JL, Alfieri R, Louis R, Duysinx B. White Blood Cells in Patients Treated with Programmed Cell Death-1 Inhibitors for Non-small Cell Lung Cancer. Lung 2021;199:549-57. [PMID: 34518898 DOI: 10.1007/s00408-021-00474-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Ma Q, Geng K, Xiao P, Zeng L. Identification and Prognostic Value Exploration of Radiotherapy Sensitivity-Associated Genes in Non-Small-Cell Lung Cancer. Biomed Res Int 2021;2021:5963868. [PMID: 34518802 DOI: 10.1155/2021/5963868] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Mojsak D, Kuklińska B, Minarowski Ł, Mróz RM. Current state of knowledge on immunotherapy in ECOG PS 2 patients. A systematic review. Adv Med Sci 2021;66:381-7. [PMID: 34315013 DOI: 10.1016/j.advms.2021.07.005] [Reference Citation Analysis]
11 Jemielita T, Li XN, Burke T, Liaw KL, Zhou W, Chen C. Augmenting Real-World Data Through Modeling Key Clinical Trial Eligibility Criteria: An Example of Patients With Non-small-Cell Lung Cancer Treated With Pembrolizumab. JCO Clin Cancer Inform 2021;5:849-58. [PMID: 34415774 DOI: 10.1200/CCI.21.00042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Ayers KL, Ma M, Debussche G, Corrigan D, McCafferty J, Lee K, Newman S, Zhou X, Hirsch FR, Mack PC, Liu JJ, Schadt EE, Chen R, Li SD. A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers. BMC Cancer 2021;21:441. [PMID: 33882890 DOI: 10.1186/s12885-021-08194-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
13 Kim DW, Tan E, Zhou JM, Schell MJ, Martinez M, Yu J, Carballido E, Mehta R, Strosberg J, Imanirad I, Kim RD. A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. Br J Cancer 2021;124:1803-8. [PMID: 33828254 DOI: 10.1038/s41416-021-01368-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
14 Wang X, Niu X, An N, Sun Y, Chen Z. Comparative Efficacy and Safety of Immunotherapy Alone and in Combination With Chemotherapy for Advanced Non-small Cell Lung Cancer. Front Oncol 2021;11:611012. [PMID: 33816241 DOI: 10.3389/fonc.2021.611012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
15 Viñal D, Gutierrez-sainz L, Martinez D, Garcia-cuesta JA, Pedregosa J, Villamayor J, Ostios L, Sanchez-cabrero D, Higuera O, Pinto A, Rodriguez-salas N, Espinosa E, de Castro J, Feliu J. Prognostic value of neutrophil-to-lymphocyte ratio in advanced cancer patients receiving immunotherapy. Clin Transl Oncol 2021;23:1185-92. [DOI: 10.1007/s12094-020-02509-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
16 Minemura H, Moriya H, Imai H, Sugiyama T, Yamada Y, Higuchi M, Kaira K, Ozaki Y, Kanazawa K, Yokouchi H, Kasai T, Kaburagi T, Suzuki H, Minato K, Shibata Y. Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab. Thorac Cancer 2020;11:3521-7. [PMID: 33044045 DOI: 10.1111/1759-7714.13695] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Ahmad A, Totiger TM, Benaduce AP, Marples B, Mihaylov IB. Establishing Correlations between Breast Tumor Response to Radio-Immunotherapy and Radiomics from Multi-Parametric Imaging: An Animal Study. Applied Sciences 2020;10:6493. [DOI: 10.3390/app10186493] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Huang Y, Shen A. The prediction potential of neutrophil-to-lymphocyte ratio for the therapeutic outcomes of programmed death receptor-1/programmed death ligand 1 inhibitors in non-small cell lung cancer patients: A meta-analysis. Medicine (Baltimore) 2020;99:e21718. [PMID: 32846790 DOI: 10.1097/MD.0000000000021718] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
19 Nakazawa Y, Gannichida A, Kageyama A, Utsumi H, Kuwano K, Kawakubo T. Involvement of Neutrophil-lymphocyte Ratio in Nivolumab Therapy-induced Hypothyroidism. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 2020;46:481-8. [DOI: 10.5649/jjphcs.46.481] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Prelaj A, Lo Russo G, Proto C, Signorelli D, Ferrara R, Galli G, De Toma A, Randon G, Pagani F, Trevisan B, Ganzinelli M, Zilembo N, Montrone M, Longo V, Pesola F, Pizzutilo P, Del Bene G, Varesano N, Galetta D, Torri V, Garassino MC, Di Maio M, Catino A. DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non–Small-Cell Lung Cancer: An External Validation. Clinical Lung Cancer 2020;21:e337-48. [DOI: 10.1016/j.cllc.2020.01.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
21 Petrova MP, Donev IS, Radanova MA, Eneva MI, Dimitrova EG, Valchev GN, Minchev VT, Taushanova MS, Boneva MV, Karanikolova TS, Gencheva RB, Zhbantov GA, Ivanova AI, Timcheva CV, P Pavlov B, Megdanova VG, Robev BS, Conev NV. Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer. Clin Exp Immunol 2020;202:353-62. [PMID: 32757277 DOI: 10.1111/cei.13505] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
22 Li Y, Zhang Z, Hu Y, Yan X, Song Q, Wang G, Chen R, Jiao S, Wang J. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs). Front Oncol 2020;10:654. [PMID: 32656072 DOI: 10.3389/fonc.2020.00654] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
23 Zhang N, Jiang J, Tang S, Sun G. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Int Immunopharmacol 2020;85:106677. [PMID: 32531712 DOI: 10.1016/j.intimp.2020.106677] [Cited by in Crossref: 38] [Cited by in F6Publishing: 43] [Article Influence: 12.7] [Reference Citation Analysis]
24 Jin J, Yang L, Liu D, Li W. Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis. BMJ Open 2020;10:e035031. [PMID: 32499266 DOI: 10.1136/bmjopen-2019-035031] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 10.0] [Reference Citation Analysis]
25 Prelaj A, Rebuzzi SE, Pizzutilo P, Bilancia M, Montrone M, Pesola F, Longo V, Del Bene G, Lapadula V, Cassano F, Petrillo P, Bafunno D, Varesano N, Lamorgese V, Mastrandrea A, Ricci D, Catino A, Galetta D. EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy. Clin Lung Cancer 2020;21:365-377.e5. [PMID: 32245624 DOI: 10.1016/j.cllc.2019.11.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 7.0] [Reference Citation Analysis]
26 Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, De Giglio A, Muzaffar M, Patel SH, Sugawara S, Burkart J, Park W, Chiari R, Sugisaka J, Otterson GA, de Lima Lopes G, Walker PR. Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. Cancer Immunol Immunother 2020;69:1177-87. [PMID: 32140762 DOI: 10.1007/s00262-020-02536-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 44] [Article Influence: 12.0] [Reference Citation Analysis]
27 Benitez JC, Recondo G, Rassy E, Mezquita L. The LIPI score and inflammatory biomarkers for selection of patients with solid tumors treated with checkpoint inhibitors. Q J Nucl Med Mol Imaging 2020;64:162-74. [PMID: 32107903 DOI: 10.23736/S1824-4785.20.03250-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 5.7] [Reference Citation Analysis]
28 Park W, Mezquita L, Okabe N, Chae YK, Kwon D, Saravia D, Auclin E, Planchard D, Caramella C, Ferrara R, Agte S, Oh M, Mudad R, Jahanzeb M, Suzuki H, Besse B, Lopes G. Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer. Br J Cancer 2020;122:340-7. [PMID: 31761899 DOI: 10.1038/s41416-019-0643-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
29 Li M, Spakowicz D, Burkart J, Patel S, Husain M, He K, Bertino EM, Shields PG, Carbone DP, Verschraegen CF, Presley CJ, Otterson GA, Kendra K, Owen DH. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers. J Cancer Res Clin Oncol 2019;145:2541-6. [PMID: 31367835 DOI: 10.1007/s00432-019-02982-4] [Cited by in Crossref: 46] [Cited by in F6Publishing: 40] [Article Influence: 11.5] [Reference Citation Analysis]
30 Tavakkoli M, Wilkins CR, Mones JV, Mauro MJ. A Novel Paradigm Between Leukocytosis, G-CSF Secretion, Neutrophil-to-Lymphocyte Ratio, Myeloid-Derived Suppressor Cells, and Prognosis in Non-small Cell Lung Cancer. Front Oncol 2019;9:295. [PMID: 31080780 DOI: 10.3389/fonc.2019.00295] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
31 Fucà G, Galli G, Poggi M, Lo Russo G, Proto C, Imbimbo M, Ferrara R, Zilembo N, Ganzinelli M, Sica A, Torri V, Colombo MP, Vernieri C, Balsari A, de Braud F, Garassino MC, Signorelli D. Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. ESMO Open 2019;4:e000457. [PMID: 30964126 DOI: 10.1136/esmoopen-2018-000457] [Cited by in Crossref: 97] [Cited by in F6Publishing: 107] [Article Influence: 24.3] [Reference Citation Analysis]
32 Jiang T, Bai Y, Zhou F, Li W, Gao G, Su C, Ren S, Chen X, Zhou C. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors. Lung Cancer 2019;130:76-83. [PMID: 30885355 DOI: 10.1016/j.lungcan.2019.02.009] [Cited by in Crossref: 42] [Cited by in F6Publishing: 49] [Article Influence: 10.5] [Reference Citation Analysis]
33 Nadal E, Massuti B, Dómine M, García-Campelo R, Cobo M, Felip E. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol Immunother 2019;68:341-52. [PMID: 30725206 DOI: 10.1007/s00262-019-02310-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 14.5] [Reference Citation Analysis]
34 Park W, Lopes G. Perspectives: Neutrophil-to-lymphocyte Ratio as a Potential Biomarker in Immune Checkpoint Inhibitor for Non-Small-Cell Lung Cancer. Clin Lung Cancer 2019;20:143-7. [PMID: 30683629 DOI: 10.1016/j.cllc.2018.12.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
35 Tan Q, Liu S, Liang C, Han X, Shi Y. Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysis. Thorac Cancer 2018;9:1220-30. [PMID: 30151899 DOI: 10.1111/1759-7714.12815] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
36 Cao D, Xu H, Xu X, Guo T, Ge W. A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studies. Oncoimmunology 2018;7:e1507262. [PMID: 30377569 DOI: 10.1080/2162402X.2018.1507262] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 6.8] [Reference Citation Analysis]
37 Putzu C, Cortinovis DL, Colonese F, Canova S, Carru C, Zinellu A, Paliogiannis P. Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab. Cancer Immunol Immunother 2018;67:1349-53. [PMID: 29947960 DOI: 10.1007/s00262-018-2182-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 6.8] [Reference Citation Analysis]